RxDoctor Payments Data

Phommalone Nguyen

Nurse Practitioner · Austin, TXNPI 1851756589

Payments from drug & device makers

$12,198in general payments, 2019–2025

Across 120 payments — averaging $101.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Sanofi$1K
  • Gilead$1K
  • Amgen$844
  • AbbVie$715
  • GSK$589
  • plus $6K from 39 others

What the payments were for

  • Food & beverage$12,188100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,198 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$40,158
Medicare patients
143
Services billed
509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$62,379
JardianceEmpagliflozin47$60,570
MounjaroTirzepatide33$48,727
TrulicityDulaglutide16$23,269
Breo ElliptaFluticasone/Vilanterol29$11,413
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate24$3,341
Duloxetine Hcl22$2,243
Albuterol Sulfate HfaAlbuterol Sulfate82$1,828
Atorvastatin Calcium189$1,552
Rosuvastatin Calcium119$1,223
Gabapentin107$1,208
Amlodipine Besylate192$1,127
Levothyroxine Sodium109$1,113
Metformin Hcl128$1,002
Tamsulosin Hcl54$920

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$147$71,99549 claims
Novo NordiskOzempic$239$62,37938 claims
Boehringer IngelheimJardiance$91$60,57047 claims
GSKBreo Ellipta$589$11,41329 claims
AbbVieSynthroid$715$56718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →